Understanding the hypoxic niche of multiple myeloma: Therapeutic implications and contributions of mouse models

DMM Disease Models and Mechanisms

Volumn 5, Issue 6, 2012, Pages 763-771

  Hu, Jinsong ^a,b   Van Valckenborgh, Els ^b   Menu, Eline ^b   De Bruyne, Elke ^b   Vanderkerken, Karin ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PIMONIDAZOLE; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; CHROMOSOME TRANSLOCATION; CHRONIC BRONCHITIS; DISEASE COURSE; GENETIC MANIPULATION; HEMATOPOIESIS; HUMAN; HYPOXIA; METASTASIS; MICROENVIRONMENT; MOUSE; MULTIPLE MYELOMA; MYELOMA; NONHUMAN; NOTE; ONCOGENE MYC; PHENOTYPE; PRIORITY JOURNAL; RABBIT; SCID MOUSE; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSGENIC MOUSE; TRANSLATIONAL RESEARCH; TUMOR GROWTH; UNFOLDED PROTEIN RESPONSE;

ANIMALS; CELL HYPOXIA; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MICE; MULTIPLE MYELOMA; OXYGEN;

EID: 84870020416     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.008961     Document Type: Note

References (115)

1. Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U. K., Pitsillides, C. M., Spencer, J. A., Kimlinger, T., Ghobrial, J. M., Jia, X. et al. (2007). Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109, 2708-2717. (Pubitemid 46482062)
2. Anderson, K. C. (2011). Oncogenomics to target myeloma in the bone marrow microenvironment. Clin. Cancer Res. 17, 1225-1233.
3. Asosingh, K., Radl, J., Van Riet, I., Van Camp, B. and Vanderkerken, K. (2000). The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol. J. 1, 351-356.
4. Asosingh, K., De Raeve, H., De Ridder, M., Storme, G. A., Willems, A., Van Riet, I., Van Camp, B. and Vanderkerken, K. (2005). Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 90, 810-817. (Pubitemid 40897223)
5. Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L. et al. (2007). Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 109, 3489-3495. (Pubitemid 46572539)
6. Azab, A. K., Runnels, J. M., Pitsillides, C., Moreau, A. S., Azab, F., Leleu, X., Jia, X., Wright, R., Ospina, B., Carlson, A. L. et al. (2009). CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113, 4341-4351.
7. Azab, A. K., Hu, J., Quang, P., Azab, F., Pitsillides, C., Awwad, R., Thompson, B., Maiso, P., Sun, J. D., Hart, C. P. et al. (2012). Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 119, 5782-5794.
8. Basak, G. W., Srivastava, A. S., Malhotra, R. and Carrier, E. (2009). Multiple myeloma bone marrow niche. Curr. Pharm. Biotechnol. 10, 335-346.
9. Benito, J., Shi, Y., Szymanska, B., Carol, H., Boehm, I., Lu, H., Konoplev, S., Fang, W., Zweidler-McKay, P. A., Campana, D. et al. (2011). Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS ONE 6, e23108.
10. Bennewith, K. L. and Dedhar, S. (2011). Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 11, 504.
11. Calimeri, T., Battista, E., Conforti, F., Neri, P., Di Martino, M. T., Rossi, M., Foresta, U., Piro, E., Ferrara, F., Amorosi, A. et al. (2011). A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 25, 707-711.
12. Carrasco, D. R., Sukhdeo, K., Protopopova, M., Sinha, R., Enos, M., Carrasco, D. E., Zheng, M., Mani, M., Henderson, J., Pinkus, G. S. et al. (2007). The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11, 349-360. (Pubitemid 46518314)
13. Chesi, M., Bergsagel, P. L., Shonukan, O. O., Martelli, M. L., Brents, L. A., Chen, T., Schröck, E., Ried, T. and Kuehl, W. M. (1998). Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91, 4457-4463. (Pubitemid 28270291)
14. Chesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K. et al. (2008). AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13, 167-180. (Pubitemid 351163163)
15. Chesi, M., Matthews, G. M., Garbitt, V. M., Palmer, S. E., Shortt, J., Lefebure, M., Stewart, A. K., Johnstone, R. W. and Bergsagel, P. L. (2012). Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120, 376-385.
16. Christian, N., Bol, A., De Bast, M., Labar, D., Lee, J., Mahy, P. and Grégoire, V. (2007). Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model. Eur. J. Nucl. Med. Mol. Imaging 34, 1348-1354. (Pubitemid 47312583)
17. Cline, J. M., Rosner, G. L., Raleigh, J. A. and Thrall, D. E. (1997). Quantification of CCI-103F labeling heterogeneity in canine solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 37, 655-662. (Pubitemid 27175321)
18. Colla, S., Tagliaferri, S., Morandi, F., Lunghi, P., Donofrio, G., Martorana, D., Mancini, C., Lazzaretti, M., Mazzera, L., Ravanetti, L. et al. (2007). The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 110, 4464-4475. (Pubitemid 351377813)
19. Colla, S., Storti, P., Donofrio, G., Todoerti, K., Bolzoni, M., Lazzaretti, M., Abeltino, M., Ippolito, L., Neri, A., Ribatti, D. et al. (2010). Low bone marrow oxygen tension and hypoxia-inducible factor-1a overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 24, 1967-1970.
20. Collingridge, D. R., Young, W. K., Vojnovic, B., Wardman, P., Lynch, E. M., Hill, S. A. and Chaplin, D. J. (1997). Measurement of tumor oxygenation: a comparison between polarographic needle electrodes and a time-resolved luminescence-based optical sensor. Radiat. Res. 147, 329-334. (Pubitemid 27114389)
21. Cook, G. J., Houston, S., Barrington, S. F. and Fogelman, I. (1998). Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J. Nucl. Med. 39, 99-103. (Pubitemid 28063179)
22. Danet, G. H., Pan, Y., Luongo, J. L., Bonnet, D. A. and Simon, M. C. (2003). Expansion of human SCID-repopulating cells under hypoxic conditions. J. Clin. Invest. 112, 126-135. (Pubitemid 38056384)
23. Davies, F. E., Dring, A. M., Li, C., Rawstron, A. C., Shammas, M. A., O'Connor, S. M., Fenton, J. A., Hideshima, T., Chauhan, D., Tai, I. T. et al. (2003). Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 102, 4504-4511. (Pubitemid 37494117)
24. DeWeerdt, S. (2011). Animal models: Towards a myeloma mouse. Nature 480, S38-S39.
25. Fenton, B. M., Rofstad, E. K., Degner, F. L. and Sutherland, R. M. (1988). Cryospectrophotometric determination of tumor intravascular oxyhemoglobin saturations: dependence on vascular geometry and tumor growth. J. Natl. Cancer Inst. 80, 1612-1619. (Pubitemid 19006810)
26. Fowler, J. A., Mundy, G. R., Lwin, S. T., Lynch, C. C. and Edwards, C. M. (2009). A murine model of myeloma that allows genetic manipulation of the host microenvironment. Dis. Model. Mech. 2, 604-611.
27. Garcia-Parra, R., Wood, D., Shah, R. B., Siddiqui, J., Hussain, H., Park, H., Desmond, T., Meyer, C. and Piert, M. (2011). Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques. Eur. J. Nucl. Med. Mol. Imaging 38, 1816-1823.
28. Garrett, I. R., Dallas, S., Radl, J. and Mundy, G. R. (1997). A murine model of human myeloma bone disease. Bone 20, 515-520. (Pubitemid 27270464)
29. Giatromanolaki, A., Bai, M., Margaritis, D., Bourantas, K. L., Koukourakis, M. I., Sivridis, E. and Gatter, K. C. (2010). Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Anticancer Res. 30, 2831-2836.
30. Goel, A., Dispenzieri, A., Geyer, S. M., Greiner, S., Peng, K. W. and Russell, S. J. (2006). Synergistic activity of the proteasome inhibitor PS-341 with nonmyeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood 107, 4063-4070. (Pubitemid 43726815)
31. Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., Albaek, C., Schrøder, H. and Ørum, H. (2008). A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther. 7, 3598-3608.
32. Griffiths, J. R. and Robinson, S. P. (1999). The OxyLite: a fibre-optic oxygen sensor. Br. J. Radiol. 72, 627-630. (Pubitemid 29355605)
33. Harrison, J. S., Rameshwar, P., Chang, V. and Bandari, P. (2002). Oxygen saturation in the bone marrow of healthy volunteers. Blood 99, 394.
34. Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G. and Anderson, K. C. (2007). Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 7, 585-598. (Pubitemid 47106630)
35. Höckel, M. and Vaupel, P. (2001). Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93, 266-276. (Pubitemid 32219813)
36. Höckel, M., Schlenger, K., Knoop, C. and Vaupel, P. (1991). Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res. 51, 6098-6102.
37. Hodgkiss, R. J., Webster, L. and Wilson, G. D. (1997). Measurement of hypoxia in vivo using a 2-nitroimidazole (NITP). Adv. Exp. Med. Biol. 428, 61-67. (Pubitemid 28127990)
38. Hou, H., Abramovic, Z., Lariviere, J. P., Sentjurc, M., Swartz, H. and Khan, N. (2010). Effect of a topical vasodilator on tumor hypoxia and tumor oxygen guided radiotherapy using EPR oximetry. Radiat. Res. 173, 651-658.
39. Hu, J., Handisides, D. R., Van Valckenborgh, E., De Raeve, H., Menu, E., Vande Broek, I., Liu, Q., Sun, J. D., Van Camp, B., Hart, C. P. et al. (2010). Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 116, 1524-1527.
40. Hu, J., Van Valckenborgh, E., Menu, E., De Raeve, H., Xu, S., Xu, D., Debruyne, E., Handisides, D. R., Van Camp, B., Hart, C. P. et al. (2011). Synergistic cytotoxicity effects of TH-302 in combination with bortezomib in multiple myeloma. Haematologica 96, 112.
41. Hu, Y., Kirito, K., Yoshida, K., Mitsumori, T., Nakajima, K., Nozaki, Y., Hamanaka, S., Nagashima, T., Kunitama, M., Sakoe, K. et al. (2009). Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol. Cancer Ther. 8, 2329-2338.
42. Hull, E. L., Conover, D. L. and Foster, T. H. (1999). Carbogen-induced changes in rat mammary tumour oxygenation reported by near infrared spectroscopy. Br. J. Cancer 79, 1709-1716. (Pubitemid 29132293)
43. Hurt, E. M., Wiestner, A., Rosenwald, A., Shaffer, A. L., Campo, E., Grogan, T., Bergsagel, P. L., Kuehl, W. M. and Staudt, L. M. (2004). Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5, 191-199. (Pubitemid 38283804)
44. Iwakoshi, N. N., Lee, A. H., Vallabhajosyula, P., Otipoby, K. L., Rajewsky, K. and Glimcher, L. H. (2003). Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat. Immunol. 4, 321-329. (Pubitemid 36432313)
45. Jeong, J. W., Bae, M. K., Ahn, M. Y., Kim, S. H., Sohn, T. K., Bae, M. H., Yoo, M. A., Song, E. J., Lee, K. J. and Kim, K. W. (2002). Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111, 709-720. (Pubitemid 35441252)
46. Komar, G., Seppänen, M., Eskola, O., Lindholm, P., Grönroos, T. J., Forsback, S., Sipilä, H., Evans, S. M., Solin, O. and Minn, H. (2008). 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J. Nucl. Med. 49, 1944-1951.
47. Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H. and Melillo, G. (2005). Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 65, 9047-9055. (Pubitemid 41377397)
48. Kotani, A., Kakazu, N., Tsuruyama, T., Okazaki, I. M., Muramatsu, M., Kinoshita, K., Nagaoka, H., Yabe, D. and Honjo, T. (2007). Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice. Proc. Natl. Acad. Sci. USA 104, 1616-1620. (Pubitemid 46214639)
49. Kuehl, W. M. (2008). Modeling multiple myeloma by AID-dependent conditional activation of MYC. Cancer Cell 13, 85-87.
50. Kyle, R. A. and Rajkumar, S. V. (2004). Multiple myeloma. N. Engl. J. Med. 351, 1860-1873.
51. Kyle, R. A. and Rajkumar, S. V. (2008). Multiple myeloma. Blood 111, 2962-2972.
52. Lee, A. H., Iwakoshi, N. N., Anderson, K. C. and Glimcher, L. H. (2003). Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. USA 100, 9946-9951. (Pubitemid 37087048)
53. Lemaire, M., Deleu, S., De Bruyne, E., Van Valckenborgh, E., Menu, E. and Vanderkerken, K. (2011). The microenvironment and molecular biology of the multiple myeloma tumor. Adv. Cancer Res. 110, 19-42.
54. Lennon, D. P., Edmison, J. M. and Caplan, A. I. (2001). Cultivation of rat marrow-derived mesenchymal stem cells in reduced oxygen tension: effects on in vitro and in vivo osteochondrogenesis. J. Cell. Physiol. 187, 345-355. (Pubitemid 32378359)
55. Leung, K. (2004). [18F]-2-(2-Nitroimidazol-1H-yl)-(3,3,3-trifluoropropyl) acetamide. MICAD-Molecular Imaging and Contrast Agent Database. Bethesda, MD: National Center for Biotechnology Information.
56. Lévesque, J. P., Winkler, I. G., Hendy, J., Williams, B., Helwani, F., Barbier, V., Nowlan, B. and Nilsson, S. K. (2007). Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow. Stem Cells 25, 1954-1965. (Pubitemid 47258173)
57. Lewis, J. S., Laforest, R., Dehdashti, F., Grigsby, P. W., Welch, M. J. and Siegel, B. A. (2008). An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J. Nucl. Med. 49, 1177-1182. (Pubitemid 351948028)
58. Loboda, A., Jozkowicz, A. and Dulak, J. (2010). HIF-1 and HIF-2 transcription factors - similar but not identical. Mol. Cells 29, 435-442.
59. Lu, L., Payvandi, F., Wu, L., Zhang, L. H., Hariri, R. J., Man, H. W., Chen, R. S., Muller, G. W., Hughes, C. C., Stirling, D. I. et al. (2009). The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc. Res. 77, 78-86.
60. Marotta, D., Karar, J., Jenkins, W. T., Kumanova, M., Jenkins, K. W., Tobias, J. W., Baldwin, D., Hatzigeorgiou, A., Alexiou, P., Evans, S. M. et al. (2011). In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. Cancer Res. 71, 779-789.
61. Martin, S. K., Diamond, P., Williams, S. A., To, L. B., Peet, D. J., Fujii, N., Gronthos, S., Harris, A. L. and Zannettino, A. C. (2010). Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica 95, 776-784.
62. Martin, S. K., Diamond, P., Gronthos, S., Peet, D. J. and Zannettino, A. C. (2011). The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 25, 1533-1542.
63. Mitsiades, C. S., Mitsiades, N. S., Bronson, R. T., Chauhan, D., Munshi, N., Treon, S. P., Maxwell, C. A., Pilarski, L., Hideshima, T., Hoffman, R. M. et al. (2003). Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 63, 6689-6696. (Pubitemid 37322948)
64. Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Kung, A. L., Davies, F. E., Morgan, G., Akiyama, M., Shringarpure, R., Munshi, N. C. et al. (2006). Antimyeloma activity of heat shock protein-90 inhibition. Blood 107, 1092-1100. (Pubitemid 43156310)
65. Moore, R. B., Chapman, J. D., Mercer, J. R., Mannan, R. H., Wiebe, L. I., McEwan, A. J. and McPhee, M. S. (1993). Measurement of PDT-induced hypoxia in Dunning prostate tumors by iodine-123-iodoazomycin arabinoside. J. Nucl. Med. 34, 405-411. (Pubitemid 23075379)
66. Morito, N., Yoh, K., Maeda, A., Nakano, T., Fujita, A., Kusakabe, M., Hamada, M., Kudo, T., Yamagata, K. and Takahashi, S. (2011). A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23). Cancer Res. 71, 339-348.
67. Munshi, N. C., Hideshima, T., Carrasco, D., Shammas, M., Auclair, D., Davies, F., Mitsiades, N., Mitsiades, C., Kim, R. S., Li, C. et al. (2004). Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 103, 1799-1806. (Pubitemid 38268976)
68. Oehler, C., O'Donoghue, J. A., Russell, J., Zanzonico, P., Lorenzen, S., Ling, C. C. and Carlin, S. (2011). 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J. Nucl. Med. 52, 437-444.
69. Ogura, T., Hamada, H., Obata-Yasuoka, M., Watanabe, H., Okuno, S., Fujiki, Y., Yamada, N., Sohda, S. and Yoshikawa, H. (2002). Antepartum assessment of fetal cystic lymphangioma by magnetic resonance imaging. Gynecol. Obstet. Invest. 53, 237-239. (Pubitemid 34977927)
70. Olenyuk, B. Z., Zhang, G. J., Klco, J. M., Nickols, N. G., Kaelin, W. G., Jr and Dervan, P. B. (2004). Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc. Natl. Acad. Sci. USA 101, 16768-16773. (Pubitemid 39601313)
71. Pacheco-Torres, J., López-Larrubia, P., Ballesteros, P. and Cerdán, S. (2011). Imaging tumor hypoxia by magnetic resonance methods. NMR Biomed. 24, 1-16.
72. Pagnucco, G., Cardinale, G. and Gervasi, F. (2004). Targeting multiple myeloma cells and their bone marrow microenvironment. Ann. N. Y. Acad. Sci. 1028, 390-399. (Pubitemid 40361840)
73. Park, E. J., Kong, D., Fisher, R., Cardellina, J., Shoemaker, R. H. and Melillo, G. (2006). Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1. Cell Cycle 5, 1847-1853. (Pubitemid 44435329)
74. Park, S. S., Kim, J. S., Tessarollo, L., Owens, J. D., Peng, L., Han, S. S., Tae Chung, S., Torrey, T. A., Cheung, W. C., Polakiewicz, R. D. et al. (2005). Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res. 65, 1306-1315. (Pubitemid 40270157)
75. Parmar, K., Mauch, P., Vergilio, J. A., Sackstein, R. and Down, J. D. (2007). Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc. Natl. Acad. Sci. USA 104, 5431-5436. (Pubitemid 47175697)
76. Pennathur-Das, R. and Levitt, L. (1987). Augmentation of in vitro human marrow erythropoiesis under physiological oxygen tensions is mediated by monocytes and T lymphocytes. Blood 69, 899-907. (Pubitemid 17057475)
77. Pilarski, L. M., Hipperson, G., Seeberger, K., Pruski, E., Coupland, R. W. and Belch, A. R. (2000). Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95, 1056-1065. (Pubitemid 30062731)
78. Podar, K. and Anderson, K. C. (2010). A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle 9, 1722-1728.
79. Poon, E., Harris, A. L. and Ashcroft, M. (2009). Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev. Mol. Med. 11, e26.
80. Prabhakar, N. R., Kumar, G. K. and Nanduri, J. (2009). Intermittent hypoxia-mediated plasticity of acute O2 sensing requires altered red-ox regulation by HIF-1 and HIF-2. Ann. N. Y. Acad. Sci. 1177, 162-168.
81. Pugh, C. W. and Ratcliffe, P. J. (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9, 677-684. (Pubitemid 36749216)
82. Rademakers, S. E., Lok, J., van der Kogel, A. J., Bussink, J. and Kaanders, J. H. (2011). Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 11, 167.
83. Radl, J., De Glopper, E. D., Schuit, H. R. and Zurcher, C. (1979). Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J. Immunol. 122, 609-613. (Pubitemid 9089221)
84. Radl, J., Croese, J. W., Zurcher, C., Van den Enden-Vieveen, M. H. and de Leeuw, A. M. (1988). Animal model of human disease. Multiple myeloma. Am. J. Pathol. 132, 593-597.
85. Raleigh, J. A., Dewhirst, M. W. and Thrall, D. E. (1996). Measuring tumor hypoxia. Semin. Radiat. Oncol. 6, 37-45. (Pubitemid 26029372)
86. Ramiro, A. R., Jankovic, M., Eisenreich, T., Difilippantonio, S., Chen-Kiang, S., Muramatsu, M., Honjo, T., Nussenzweig, A. and Nussenzweig, M. C. (2004). AID is required for c-myc/IgH chromosome translocations in vivo. Cell 118, 431-438. (Pubitemid 39485663)
87. Ribatti, D., Nico, B. and Vacca, A. (2006). Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 25, 4257-4266. (Pubitemid 44100496)
88. Ruas, J. L. and Poellinger, L. (2005). Hypoxia-dependent activation of HIF into a transcriptional regulator. Semin. Cell Dev. Biol. 16, 514-522. (Pubitemid 41247874)
89. Semenza, G. (2002). Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 64, 993-998.
90. Semenza, G. L. (2001). HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107, 1-3.
91. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732.
92. Shin, D. H., Chun, Y. S., Lee, D. S., Huang, L. E. and Park, J. W. (2008). Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111, 3131-3136.
93. Shou, Y., Martelli, M. L., Gabrea, A., Qi, Y., Brents, L. A., Roschke, A., Dewald, G., Kirsch, I. R., Bergsagel, P. L. and Kuehl, W. M. (2000). Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl. Acad. Sci. USA 97, 228-233. (Pubitemid 30055813)
94. Skouby, A. R. (1976). Haematologic adaptation in patients with chronic bronchitis and pulmonary insufficiency. Acta Med. Scand. 199, 185-190.
95. Taniguchi, M. and Taniguchi, T. (1975). Thermally induced conformational changes of tobacco mosaic virus and their protein assemblies. Biochim. Biophys. Acta 386, 1-17.
96. Tassone, P., Neri, P., Carrasco, D. R., Burger, R., Goldmacher, V. S., Fram, R., Munshi, V., Shammas, M. A., Catley, L., Jacob, G. S. et al. (2005). A clinically relevant SCIDhu in vivo model of human multiple myeloma. Blood 106, 713-716. (Pubitemid 40981270)
97. Tøndevold, E., Eriksen, J. and Jansen, E. (1979). Observations on long bone medullary pressure in relation to mean arterial blood pressure in the anaesthetized dog. Acta Orthop. Scand. 50, 527-531. (Pubitemid 10211567)
98. Urashima, M., Chen, B. P., Chen, S., Pinkus, G. S., Bronson, R. T., Dedera, D. A., Hoshi, Y., Teoh, G., Ogata, A., Treon, S. P. et al. (1997). The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 90, 754-765. (Pubitemid 27299116)
99. Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F. and Dammacco, F. (1994). Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 87, 503-508. (Pubitemid 24230014)
100. van der Sanden, B. P. J., Heerschap, A., Simonetti, A. W., Rijken, P. F., Peters, H. P., Stüben, G. and van der Kogel, A. J. (1999). Characterization and validation of noninvasive oxygen tension measurements in human glioma xenografts by 19F-MR relaxometry. Int. J. Radiat. Oncol. Biol. Phys. 44, 649-658.
101. Van Valckenborgh, E., Bakkus, M., Munaut, C., Noël, A., St Pierre, Y., Asosingh, K., Van Riet, I., Van Camp, B. and Vanderkerken, K. (2002). Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int. J. Cancer 101, 512-518.
102. Vanderkerken, K., Asosingh, K., Croucher, P. and Van Camp, B. (2003). Multiple myeloma biology: lessons from the 5TMM models. Immunol. Rev. 194, 196-206. (Pubitemid 36896125)
103. Vaupel, P. (2009). Prognostic potential of the pre-therapeutic tumor oxygenation status. Adv. Exp. Med. Biol. 645, 241-246.
104. Vaupel, P., Schlenger, K., Knoop, C. and Höckel, M. (1991). Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 51, 3316-3322.
105. Weljie, A. M., Bondareva, A., Zang, P. and Jirik, F. R. (2011). (1)H NMR metabolomics identification of markers of hypoxia-induced metabolic shifts in a breast cancer model system. J. Biomol. NMR 49, 185-193.
106. Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G. and Powis, G. (2004). Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 3, 233-244. (Pubitemid 39193698)
107. Wilson, A. and Trumpp, A. (2006). Bone-marrow haematopoietic-stem-cell niches. Nat. Rev. Immunol. 6, 93-106. (Pubitemid 43361585)
108. Wilson, D. F. and Cerniglia, G. J. (1992). Localization of tumors and evaluation of their state of oxygenation by phosphorescence imaging. Cancer Res. 52, 3988-3993.
109. Wilson, W. R. and Hay, M. P. (2011). Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393-410.
110. Xin, X., Abrams, T. J., Hollenbach, P. W., Rendahl, K. G., Tang, Y., Oei, Y. A., Embry, M. G., Swinarski, D. E., Garrett, E. N., Pryer, N. K. et al. (2006). CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin. Cancer Res. 12, 4908-4915. (Pubitemid 44338578)
111. Yaccoby, S., Barlogie, B. and Epstein, J. (1998). Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92, 2908-2913. (Pubitemid 28469106)
112. Yata, K. and Yaccoby, S. (2004). The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18, 1891-1897. (Pubitemid 39530021)
113. Yeo, E. J., Chun, Y. S., Cho, Y. S., Kim, J., Lee, J. C., Kim, M. S. and Park, J. W. (2003). YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95, 516-525. (Pubitemid 36511622)
114. Zhang, J., Sattler, M., Tonon, G., Grabher, C., Lababidi, S., Zimmerhackl, A., Raab, M. S., Vallet, S., Zhou, Y., Cartron, M. A. et al. (2009). Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res. 69, 5082-5090.
115. Zhao, D., Chang, C. H., Kim, J. G., Liu, H. and Mason, R. P. (2011). In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome. Int. J. Radiat. Oncol. Biol. Phys. 80, 574-581.